Research ArticleBasic Science Investigations

Preclinical Evaluation of 68Ga-Labeled 1,4,7-Triazacyclononane-1,4,7-Triacetic Acid-Ubiquicidin as a Radioligand for PET Infection Imaging

Thomas Ebenhan, Jan Rijn Zeevaart, Jacobus D. Venter, Thavendran Govender, Gert H. Kruger, Neil V. Jarvis and Mike M. Sathekge
Journal of Nuclear Medicine February 2014, 55 (2) 308-314; DOI: https://doi.org/10.2967/jnumed.113.128397

Article Figures & Data

Figures

  • FIGURE 1.
    FIGURE 1.

    Coronal PET images acquired at 60 min after intravenous injection of 48–155 MBq of 68Ga-NOTA-UBI29-41 into healthy rabbits (NZR-1) (A) and 37–174 MBq of 68Ga-NOTA-UBI29-41 into rabbits with muscular infection (right thigh) and with sterile muscular inflammation muscle (left thigh) (NZR-2) (B). Axial PET/CT images displaying hind thighs 5 (C), 30 (D), 60 (E), and 90 (F) min after injection.

  • FIGURE 2.
    FIGURE 2.

    Activity concentration of 68Ga-NOTA-UBI29-41 in blood (A) and urine (B) obtained from healthy rabbits (group NZR-1). Animals were injected intravenously with 96 ± 35 MBq/kg.

Tables

  • TABLE 1

    Organ and Tissue Biodistribution of 68Ga-NOTA-UBI29-41 in Healthy Rabbits

    Percentage of injected dose (min) after injection*
    Organ or tissue3060120
    Heart0.66 ± 0.170.63 ± 0.310.55 ± 0.06
    Liver5.71 ± 2.433.82 ± 0.922.24 ± 0.96
    Spleen1.08 ± 0.520.73 ± 0.310.75 ± 0.09
    Bladder, urinary tract25.10 ± 6.0927.55 ± 6.5033.09 ± 7.24
    Kidney2.86 ± 1.104.23 ± 1.653.17 ± 0.71
    Hind leg muscle0.12 ± 0.050.10 ± 0.030.11 ± 0.02
    Front leg muscle0.11 ± 0.040.10 ± 0.030.10 ± 0.02
    Lung0.42 ± 0.180.46 ± 0.160.41 ± 0.06
    Brain0.05 ± 0.020.05 ± 0.020.06 ± 0.02

    • ↵* Values represent mean ± SD of n > 3 animals.

  • TABLE 2

    Organ and Tissue Concentration of 68Ga-NOTA-UBI29-41 in Healthy Rabbits

    SUV (min) after injection*
    Organ or tissue3060120
    Heart0.80 ± 0.240.65 ± 0.160.53 ± 0.24
    Liver1.91 ± 1.171.84 ± 1.320.67 ± 0.27
    Spleen1.65 ± 0.861.62 ± 0.950.74 ± 0.29
    Bladder, urinary tract19.96 ± 8.4714.16 ± 4.2410.65 ± 4.90
    Kidney3.20 ± 0.883.39 ± 0.742.85 ± 0.63
    Hind leg muscle0.25 ± 0.080.20 ± 0.040.12 ± 0.02
    Front leg muscle0.24 ± 0.050.20 ± 0.050.10 ± 0.03
    Lung0.60 ± 0.220.53 ± 0.220.35 ± 0.10
    Brain0.24 ± 0.110.16 ± 0.070.13 ± 0.07

    • ↵* Values represent mean ± SD of n > 3 animals.

  • TABLE 3

    Accumulation of 68Ga-NOTA-UBI29-41 in Staphylococcus Aureus–Infected Rabbits

    PET/CT image acquisition (min) after injection†
    T/NT* ratio5306090
    Normal hind muscle to normal front muscle1.02‡0.99 ± 0.171.02 ± 0.19ND
    Infected muscle to normal muscle3.16 ± 0.893.16 ± 0.754.35 ± 0.853.84 ± 1.53
    Inflamed muscle to normal muscle1.12 ± 0.141.12 ± 0.071.25 ± 0.250.98 ± 0.19
    Infected muscle to inflamed muscle2.86 ± 0.932.90 ± 0.503.54 ± 0.863.80 ± 0.90
    Infected muscle to liver0.97 ± 0.100.97 ± 0.521.35 ± 0.330.81 ± 0.59

    • ↵* Nontargeted tissue (frontal leg triceps).

    • ↵† Values represent mean ± SD of > 3 animals/group.

    • ↵‡ Lung-to-muscle ratio calculated from single animal.

    • ND = value not determined.

  • TABLE 4

    Pulmonary Distribution of 68Ga-NOTA-UBI29-41 in Rabbits: Quantification of Lung Tissue

    PET/CT image acquisition (min) after injection†
    T/NT* ratio (lung to muscle)5306090120
    Healthy (NZR-1)ND2.5 ± 0.632.5 ± 0.53ND3.0 ± 0.55
    Infection/inflammation (NZR-2)1.9 ± 0.532.5 ± 0.792.2 ± 0.492.7 ± 1.01ND
    Asthma (NZR-3)2.1‡2.4 ± 0.452.5 ± 0.44NDND

    • ↵* Nontargeted tissue (frontal leg triceps).

    • ↵† Values represent mean ± SD of > 3 animals/group.

    • ↵‡ Lung-to-muscle ratio calculated from single animal.

    • ND = value not determined.

Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Bookmark this article

Jump to section

Keywords